Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients

Genetics Research

Volumn 96, Issue , 2014, Pages

  Carneiro, Juliana G ^a,b   Couto, Patricia G ^b   Bastos Rodrigues, Luciana ^b   Bicalho, Maria Aparecida C ^b   Vidigal, Paula V ^b   Vilhena, Alyne ^c   Amaral, Nilson F ^c   Bale, Allen E ^d   Friedman, Eitan ^e   De Marco, Luiz ^b  

^a Centro de Ensino Superior e Desenvolvimento   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Hospital Sarah Kubitscheck   (Brazil)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; THYROID TRANSCRIPTION FACTOR 1; GENOMIC DNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; BRAF PROTEIN, HUMAN; DNA BINDING PROTEIN; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PTEN PROTEIN, HUMAN; RAS PROTEIN; TTF1 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; CODON; CONTROLLED STUDY; EXON; FEMALE; GENE DELETION; GENE EXPRESSION; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; INDEL MUTATION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; SOMATIC MUTATION; AFRICAN; AMERICAN INDIAN; BRAZILIAN; CANCER PATIENT; CANCER STAGING; EUROPEAN; GENE MUTATION; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; SQUAMOUS CELL LUNG CARCINOMA; ADENOCARCINOMA; BRAZIL; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BRAZIL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84899821444     PISSN: 00166723     EISSN: 14695073     Source Type: Journal    
DOI: 10.1017/S0016672314000032     Document Type: Article

References (68)

1. Amoedo, N. D., Castelo-Branco, M. T., Paschoal, M. E., Pezzuto, P., Esperança, A. B., Rumjanek, V. M. & Rumjanek, F. D. (2009). Expression of ABC transporters, p53, Bax, Bcl-2 in an archival sample of non-small cell lung cancer bearing a deletion in the EGFR gene. International Journal of Molecular Medicine 23, 609-614.
2. Arrieta, O., Cardona, A. F., Bramuglia, G. F., Gallo, A., Campos-Parra, A. D., Serrano, S., Castro, M., Avilés, A., Amorin, E., Kirchuk, R., Cuello, M., Borbolla, J., Riemersma, O., Becerra, H. & Rosell, R. (2011). Genotyping non-small cell lung cancer (NSCLC) in Latin America. Journal of Thoracic Oncology 6, 1955-1959.
3. Bastos-Rodrigues, L., Pimenta, J. R. & Pena, S.D. (2006). The genetic structure of human populations studied through short insertion-deletion polymorphisms. Annals of Human Genetics 70, 658-665.
4. Berghmans, T., Mascauxa, C., Hallerb, A., Meerta, A. P., Van Houttec, P. & Sculier, J. P. (2008). EGFR, TTF-1 and Mdm2 expression in stage III non-small cell lung cancer: a positive association. Lung Cancer 62, 35-44.
5. Borràs, E., Jurado, I., Hernan, I., Gamundi, M. J., Dias, M., Martí, I., Mañé, B., Arcusa, A., Agúndez, J. A., Blanca, M. & Carballo, M. (2011). Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer 11, 406.
6. Brevet, M., Johnson, M. L., Azzoli, C. G. & Ladanyi, M. (2011). Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 73, 96-102.
7. Cantley, L. C. & Neel, B. G. (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proceedings of the National Academy of Sciences USA 96, 4240-4245.
8. Cantwell-Dorris, E. R. (2011). BRAFV600E: Implications for carcinogenesis and molecular therapy. Molecular Cancer Therapeutics 10, 385-394.
9. Cote, M. L., Kardia, S. L., Wenzlaff, A. S., Ruckdeschel, J. C. & Schwartz, A. G. (2005). Risk of lung cancer among white and black relatives of individuals with early-onset lung cancer. JAMA 293, 3036-3042.
10. Cote, M. L., Haddad, R. & Edwards, D. J. (2011). Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. Journal of Thoracic Oncology 6, 627-630.
11. Dearden, S., Stevens, J., Wu, Y. L. & Blowers, D. (2013). Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Annals of Oncology 24, 2371-2376.
12. Dhomen, N. & Marais, R. (2009). BRAF signaling and targeted therapies in melanoma. Hematology/Oncology Clinics of North America 23, 529-545.
13. Endersby, R. & Baker, S. J. (2008). PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 27, 5416-5430.
14. Forgacs, E., Biesterveld, E. J., Sekido, Y., Fong, K., Muneer, S., Wistuba, I. I., Milchgrub, S., Brezinschek, R., Virmani, A., Gazdar, A. F. & Minna, J. D. (1998). Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 17, 1557-1565.
15. Gaughan, E. M. & Costa, D. B. (2011). Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Therapeutic Advances in Medical Oncology 3, 113-125.
16. Girard, N. (2013). Other signalization targets. Target Oncology 8, 69-77.
17. Haiman, C. A., Stram, D. O., Wilkens, L. R., Pike, M. C., Kolonel, L. N., Henderson, B. E. & Le Marchand, L. (2006). Ethnic and racial differences in the smoking-related risk of lung cancer. New England Journal of Medicine 354, 333-342.
18. Han, S.W., Kim, T. Y., Jeon, Y. K., Hwang, P. G., Im, S. A., Lee, K. H., Kim, J. H., Kim, D.W., Heo, D. S., Kim, N. K., Chung, D. H. & Bang, Y. J. (2006). Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clinical Cancer Research 12, 2538-2544.
19. Heigener, D. F. & Reck, M. (2011). Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: impact on treatment beyond gefitinib and erlotinib. Advances in Therapy 28, 126-133.
20. Hunt, J. D., Strimas, A., Eyer, M., Haddican, M., Luckett, B. G., Ruiz, B., Axelrad, T.W., Backes, W. L. & Fontham, E. T. (2002). Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens. Cancer Epidemiology, Biomarkers and Prevention 11, 1405-1412.
21. Irmer, D., Funk, J. O. & Blaukat, A. (2007). EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy. Oncogene 26, 5693-5701.
22. Jin, G., Kim, M. J., Jeon, H. S., Choi, J. E., Kim, D. S., Lee, E. B., Cha, S. I., Yoon, G. S., Kim, C. H., Jung, T. H. & Park, J. Y. (2010). PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 69, 279-283.
23. Kadara, H., Kabbout, M. & Wistuba, I. (2011). Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology 17, 50-65.
24. Kawaguchi, T., Matsumura, A., Fukai, S., Tamura, A., Saito, R., Zell, J. A., Maruyama, Y., Ziogas, A., Kawahara, M. & Ignatius, S.H. (2010). Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. Journal of Thoracic Oncology 5, 1001-1010.
25. Keedy, V. L., Temin, S., Somerfield, M. R., Beasley, M. B., Johnson, D. H., McShane, L. M., Milton, D. T., Strawn, J. R., Wakelee, H. A. & Giaccone, G. (2011). American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. Journal of Clinical Oncology 29, 2121-2127.
26. Kondo, M., Yokoyama, T., Fukui, T., Yoshioka, H., Yokoi, K., Nagasaka, T., Imaizumi, K., Kume, H., Hasegawa, Y., Shimokata, K. & Sekido, Y. (2005). Mutations of epidermal growth factor receptor of nonsmall cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Lung Cancer 50, 385-391.
27. Kumar, K., Brim, H., Giardiello, F., Smoot, D. T., Nouraie, M., Lee, E. L. & Ashktorab, H. (2009). Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. Clinical Cancer Research 15, 1155-1161.
28. Lahiri, D. K. & Nurnberger, J. I. (1991). A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Research 11, 5444.
29. Lee, S. Y., Kim, M. J., Jin, G., Yoo, S. S., Park, J. Y., Choi, J. E., Jeon, H. S., Cho, S., Lee, E. B., Cha, S. I., Park, T. I., Kim, C. H., Jung, T. H. & Park, J. Y. (2010). Somatic mutations in EGFR signaling pathway genes. Journal of Thoracic Oncology 5, 1734-1740.
30. Leidner, R. S., Fu, P., Clifford, B., Hamdan, A., Jin, C., Eisenberg, R., Boggon, T. J., Skokan, M., Franklin, W. A., Cappuzzo, F., Hirsch, F. R., Varella-Garcia, M. & Halmos, B. (2009). Genetic abnormalities of the EGFR pathway in African American patients with non-smallcell lung cancer. Journal of Clinical Oncology 27, 5620-5626.
31. Li, G., Zhao, J., Peng, X., Liang, J., Deng, X. & Chen, Y. (2012). The mechanism involved in the loss of PTEN expression in NSCLC tumor cells. Biochemical and Biophysical Research Communications 418, 547-552.
32. Li, T., Kung, H. J., Mack, P. C. & Gandara, D. R. (2013). Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. Journal of Clinical Oncology 31, 1039-1049.
33. Maeshima, A. M., Omatsu, M., Tsuta, K., Asamura, H. & Matsuno, Y. (2008). Immunohistochemical expression of TTF-1 in various cytological subtypes of primary lung adenocarcinoma, with special reference to intratumoral heterogeneity. Pathology International 58, 31-37.
34. Marchetti, A., Felicioni, L., Malatesta, S., Grazia Sciarrotta, M., Guetti, L., Chella, A., Viola, P., Pullara, C., Mucilli, F. & Buttitta, F. (2011). Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. Journal of Clinical Oncology 29, 3574-35479.
35. Matsuo, K., Ito, H., Yatabe, Y., Hiraki, A., Hirose, K., Wakai, K., Kosaka, T., Suzuki, T., Tajima, K. & Mitsudomi, T. (2007). Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a casecontrol study in Japanese. Cancer Science 98, 96-101.
36. Maxwell, G. L., Risinger, J. I., Hayes, K. A., Alvarez, A. A., Dodge, R. K., Barrett, J. C. & Berchuck, A. (2000). Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clinical Cancer Research 6, 2999-3005.
37. Miller, S. A., Dykes, D. D. & Polesky, H. F. (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research 16, 1215.
38. Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saij, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J., Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L., Armour, A. A. & Fukuoka, M. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine 361, 947-957.
39. Murray, S., Timotheadou, E., Linardou, H., Vrettou, A. V., Kostopoulos, I., Skrickova, J., Papakostantinou, C., Christodoulou, C., Pectasides, D., Samantas, E., Papakostas, P., Skarlos, D. V., Kosmidis, P. & Fountzilas, G. (2006). Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Lung Cancer 52, 225-233.
40. Ordóñez, N. G. (2012). Thyroid transcription factor-1 is not expressed in squamous cell carcinomas of the lung: an immunohistochemical study with review of the literature. Applied Immunohistochemistry and Molecular Morphology 20, 525-530.
41. Oxnard, G. R., Binder, A., & Jänne, P. A. (2013). New targetable oncogenes in non-small-cell lung cancer. Journal of Clinical Oncology 31, 1097-1104.
42. Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E. & Meyerson, M. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500.
43. Pan, Q., Pao, W., Ladanyi, M. (2005). Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. The Journal of Molecular Diagnostics 7, 396-403.
44. Pandolfi, P. P. (2008). P-TEN exciting years: from the cytosol to the nucleus and back to keep cancer at bay. Oncogene 27, 5386.
45. Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G. & Varmus, H. E. (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Medicine 2, e17.
46. Pena, S. D., Bastos-Rodrigues, L., Pimenta, J. R. & Bydlowski, S. P. (2009). DNA tests probe the genomic ancestry of Brazilians. Brazilian Journal of Medical and Biological Research 42, 870-876.
47. Pratilas, C. A., Hanrahan, A. J., Halilovic, E., Persaud, Y., Soh, J., Chitale, D., Shigematsu, H., Yamamoto, H., Sawai, A., Janakiraman, M., Taylor, B. S., Pao, W., Toyooka, S., Ladanyi, M., Gazdar, A., Rosen, N. & Solit, D. B. (2008). Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Research 68, 9375-9383.
48. Reinersman, J. M., Johnson, M. L., Riely, G. J., Chitale, D. A., Nicastri, A. D., Soff, G. A., Schwartz, A. G., Sima, C. S., Ayalew, G., Lau, C., Zakowski, M. F., Rusch, V.W., Ladanyi, M. & Kris, M. G. (2011). Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. Journal of Thoracic Oncology 6, 28-31.
49. Reungwetwattana, T., Weroha, S. J. & Molina, J. R. (2012). Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clinical Lung Cancer 13, 252-266.
50. Riely, G. J., Politi, K. A., Miller, V. A. & Pao, W. (2006). Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clinical Cancer Research 12, 7232-7241.
51. Riely, G. J., Kris, M. G., Rosenbaum, D., Marks, J., Li, A., Chitale, D. A., Nafa, K., Riedel, E. R., Hsu, M., Pao, W., Miller, V. A. & Ladanyi, M. (2008). Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clinical Cancer Research 14, 5731-5734.
52. Riely, G. J., Marks, J. & Pao, W. (2009). KRAS mutations in non-small cell lung cancer. Proceedings of the American Thoracic Society 6, 201-205.
53. Rosell, R., Moran, C., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., Insa, A., Massuti, B., Gonzalez- Larriba, J. L., Paz-Ares, L., Bover, I., Garcia- Campelo, R., Moreno, M. A., Catot, S., Rolfo, C., Reguart, N., Palmero, R., Sánchez, J. M., Bastus, R., Mayo, C., Bertran-Alamillo, J., Molina, M. A., Sanchez, J. J. & Taron, M. (2009). Screening for epidermal growth factor receptor mutations in lung cancer. New England Journal of Medicine 361, 958-967.
54. Sasaki, H., Kawano, O., Endo, K., Suzuki, E., Haneda, H., Yukiue, H., Kobayashi, Y., Yano, M. & Fujii, Y. (2006). Uncommon V599E BRAF mutations in Japanese patients with lung cancer. Journal of Surgical Research 133, 203-206.
55. Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., Fujisawa, T., Feng, Z., Roth, J. A., Herz, J., Minna, J. D. & Gazdar, A. F. (2005). Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. Journal of the National Cancer Institute 97, 339-346.
56. Simpson, L. & Parsons, R. (2001). PTEN: life as a tumor suppressor. Experimental Cell Research 264, 29-41.
57. Su, Z., Dias-Santagata, D., Duke, M., Hutchinson, K., Lin, Y. L., Borger, D. R., Chung, C. H., Massion, P. P., Vnencak-Jones, C. L., Iafrate, A. J. & Pao, W. (2011). A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. Journal of Molecular Diagnostics 13, 74-84.
58. Suda, K., Tomizawa, K. & Mitsudomi, T. (2010). Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Review 29, 49-60.
59. Tang, J. M., He, Q. Y., Guo, R. X. & Chang, X. J. (2006). Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51, 181-191.
60. Tang, M., Iijima, M., Kamimura, Y., Chen, L., Long, Y. & Devreotes, P. (2011). Disruption of PKB signaling restores polarity to cells lacking tumor suppressor PTEN. Molecular Biology of the Cell 22, 437-447.
61. Tapia, C., Savic, S., Bihl, M., Rufle, A., Zlobec, I., Terracciano, L. & Bubendorf, L. (2009). EGFR mutation analysis in non-small-cell lung cancer: experience from routine diagnostics. Der Pathologe 30, 384-392. [In German]
62. Travis, W. D., Brambilla, E. & Riely, G. J. (2013). New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. Journal of Clinical Oncology 31, 992-1001.
63. Vlastos, F., Zinszner, J., Hussenet, T., du Manoir, S., Vordonis, L., Nikolakopoulou, S., Hardavella, G., Lacomme, S., Vignaud, J. M. & Martinet, N. (2010). Mapping EGFR1 mutations in patients with lung adenocarcinoma. Diagnostic Molecular Pathology 19, 209-217.
64. Wislez, M., Antoine, M., Baudrin, L., Poulot, V., Neuville, A., Pradere, M., Longchampt, E., Isaac-Sibille, S., Lebitasy, M. P. & Cadranel, J. (2010). Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer 68, 185-191.
65. Xing, M. (2005). BRAF mutation in thyroid cancer. Endocrine Related Cancer 12, 245-262.
66. Yatabe, Y., Kosaka, T., Takahashi, T. & Mitsudomi, T. (2005). EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. American Journal of Surgical Pathology 29, 633-639.
67. Yokomizo, A., Tindall, D. J., Drabkin, H., Gemmill, R., Franklin, W., Yang, P., Sugio, K., Smith, D. I. & Liu, W. (1998). PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 17, 475-479.
68. Zuo, Z., Chen, S. S., Chandra, P. K., Galbincea, J. M., Soape, M., Doan, S., Barkoh, B. A., Koeppen, H., Medeiros, L. J. & Luthra, R. (2009). Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Modern Pathology 22, 1023-1031.